Table 3.

Clinical and biochemical outcomes in children and adolescents with an intact colon up to 18 months follow-up in the propensity score-matched cohort.

	South Asian	Caucasian	p-value	Adjusted OR [95% CI]b
CD outcome in entire PS cohortc
Sustained CSF remission 12-18 mo	27 [75%]	40 [58%]	0.08	2.40 [0.99–5.84]
CSF remission 18 mo	25 [83%]	51 [76%]	0.43	1.48 [0.48–4.56]
Biochemical remission 18 mo	21 [75%]	45 [78%]	0.79	0.96 [0.33–2.82]
UC outcome in entire PS cohorta,c
Sustained CSF remission 12‐18 mo	27 [59%]	39 [57%]	0.82	1.14 [0.53–2.45]
CSF remission 18 mo	34 [76%]	50 [74%]	0.81	1.12 [0.47–2.67]
Biochemical remission 18 mo	31 [82%]	41 [72%]	0.28	1.79 [0.65–4.92]
UC outcome in patients on 5-ASA monotherapy only at 18 moa
Sustained CSF remission 12‐18 mo	10 [67%]	16 [53%]	0.39	1.75 [0.48–6.36]
CSF remission 18 mo	12 [80%]	23 [79%]	0.96	1.04 [0.22–4.93]
Biochemical remission 18 mo	10 [77%]	15 [68%]	0.58	1.56 [0.32–7.49]

Corticosteroid free [CSF] clinical remission; wPCDAI≤12 or PUCAI <10 and no corticosteroids for ≥4 weeks. Biochemical remission; CSF clinical remission and CRP <5. Sustained CSF remission: physician global assessment score reported as quiescent and no use of corticosteroids during the interval period.

CD, Crohn’s disease; UC, ulcerative colitis; mo, months; wPCDAI, weighted paediatric Crohn’s Disease Activity Index; PUCAI, Paediatric Ulcerative Colitis Activity Index; OR, odds ratio; CI, confidence interval; PS, propensity score; CSF, corticosteroid-free; 5-ASA, 5-aminosalicylates; CRP, C-reactive protein.

^aAnalysis was performed in those with an intact colon.

^bOdds ratio comparing South Asian with Caucasian.

^cOdds ratio comparing South Asian with Caucasian adjusted for infliximab exposure at 6 months.